v3.26.3
Segment Information - Schedule of Segment Reporting Financial Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2024
Revenue      
Total revenue $ 63,001 $ 65,324 $ 67,635
Operating expenses:      
Research and development 88,546 106,740 131,476
General and administrative 36,835 43,933 57,850
Total operating expenses 125,381 150,673 189,326
Loss from operations (62,380) (85,349) (121,691)
Other income (expense):      
Interest expense (14,074) (7,681) (10,940)
Interest and investment income, net 8,225 9,442 14,770
Change in fair value of Series 1 nonconvertible preferred stock 21 39 73
Total other income (expense), net (5,828) 1,800 3,903
Loss before income taxes (68,208) (83,549) (117,788)
Income tax benefit (expense) (40) 1,660 1,743
Net loss (68,248) (81,889) (116,045)
Royalty [Member]      
Revenue      
Total revenue 63,001 65,324 67,635
Virology [Member]      
Operating expenses:      
Research and development 25,898 59,808 86,367
Virology [Member] | RSV [Member]      
Operating expenses:      
Research and development 25,898 59,808 86,367
Immunology [Member]      
Operating expenses:      
Research and development 55,003 43,780 31,038
Immunology [Member] | MRGPRX2 [Member]      
Operating expenses:      
Research and development 12,393 9,114 6,525
Immunology [Member] | KIT [Member]      
Operating expenses:      
Research and development 17,067 18,052 19,822
Immunology [Member] | STAT6 [Member]      
Operating expenses:      
Research and development 25,543 16,614 4,691
Other programs [Member]      
Operating expenses:      
Research and development 7,645 3,152 14,071
Other programs [Member] | Other Pipeline Programs [Member]      
Operating expenses:      
Research and development 776 938 5,600
Other programs [Member] | Early discovery [Member]      
Operating expenses:      
Research and development $ 6,869 $ 2,214 $ 8,471